This action might not be possible to undo. Are you sure you want to continue?
Year of Establishment Founder
February 1984 Dr. Anji Reddy Entrepreneur Scientist
1980-84 Standard Organics Limited 1976-80 Uniloids Limited 1969-75 Indian Drugs and Pharmaceuticals Limited
Dr.Reddy’s under Dr. Anji Reddy Pioneer and Trendsetter in Indian Pharmaceutical industry Turned around Indian Bulk Drug industry Indian Bulk Drug industry
Mid-80s Mid-90s 2000 onwards Import-dependent Self-reliant Export-oriented industry
Transformed industry sobriquet from ‘Immitators’ to ‘Innovators’ 1st Indian Pharma Company to take up Drug Discovery research
We are …
An Integrated Global Pharmaceutical Company
Our Purpose: Our Vision:
“To help people lead healthier lives”
“To become a discovery led global pharmaceutical company”
Dual Impact Approach
• • Improve accessibility through generic pharmaceuticals Satisfy unmet medical needs through new and improved pharmaceuticals
Global Presence Focus on US. Brazil. India and Russia Wholly-owned subsidiaries in the USA. Russia. Turkey and Mexico Joint Ventures in China. South Africa and Australia Representative Offices in 16 countries 3rd party Distribution setups in 23 countries . UK. Germany. New Zealand.
Medium Term Value Creation Medium-Long Term Value Creation PS AI .Our Businesses Near.
Our Businesses : APIs • Consistent Track Record : Profitable growth in last four years • Products Commercialized in Regulated Market : More than 25 • Products Commercialized in Near-Regulated Markets : More than 100 • Strong Relationships • Add Strategic Value • Core Platform • Strong Customer Base : Top tier global and regional generic players in key markets : To the company’s finished dosage businesses globally : Provides high degree of vertical integration & cost advantage : Servicing more than 800 customers spread over 100 countries and Six continents .
Reddy’s has • 127 Active US DMFs • 50 Canadian DMFs • 69 EDMFs • 21 CEPs . 3 in US DMF filings Globally • Ranked No.Our Businesses : APIs Regulatory Strengths • Ranked No. 1 in US DMF filings from India • Dr.
UK : Supply chain and ERP systems (SAP R/3) : Contributing to a sustainable world with zero liquid discharge systems : Developed and commercialized Highly Potent Active for Oncology formulations • Fully Integrated Operations • Environmental Compliance • HPAI Ingredients .Our Businesses : APIs Operations Capabilities • Capabilities in Major Chemistries : 24 • Reaction Volume with Concurrent scaling-up and Piloting : Over 2.3Mn Litres • State-of-the-art Equipment and Instruments : Six USFDA approved plants in India One USFDA approved plant in Mexico One USFDA inspected plant in Mirfield.
Our Businesses : Custom Pharmaceutical Services We are a partner of choice for Innovator companies with service offerings spanning the entire value chain •Strengths : Mexico provides critical mass and broadens relationship with Innovator companies Dowpharma/Chirotech acquisition in UK provides proprietary chiral and biocatalysis technology •Services : Process research Analytical development Preformulation and formulation development Clinical trial supplies Pilot scale manufacture ( API and Dosage Product regulatory support Forms) •Broad Client Base • • Large Pharma : More than Five Emerging Pharma. Biotech & Fine Chemical : More than Ten .
Total strength of 60 scientists • Organic Chemistry Labs : Twenty One • Formulation Development: Three • Analytical Labs • Kilo Lab • Unique Manufacturing Capabilities : Three : One : Steroid and Cytotoxic .Our Businesses : Custom Pharmaceutical Services • R&D facilities : Three Centres with over 300 chemists & engineers well-skilled in cGMP requirement Separate Labs for Formulation development .
Cetirizine 10mg in FY08 EU Started operations in 1999. Acquisition of BMS in 2002 – over 30 products Acquisition of betapharm in 2006 – 145 products 5th largest branded generic player in Germany Acquisition of Jet Generici Srl. Germany. U NA Established in 2001. In Italy .Our Businesses : Generic Finished Dosages Current Presence: USA. Over 29 products in the market 11 new products families launched in FY08 Launched Private Label (Store Brand) OTC Ranitidine 150. Ranitidine 75.
AMERISTAR • DIANA Award for North America recognizing efficient & innovative business practices. Patent & manufacturing expertise • Cost-effective/high speed development • Track record of successful ‘Day 1 launches’ with significant market share • Our expertise in packaging recognized – WORLDSTAR. .Our Businesses : Generic Finished Dosages Key Strengths • Excellent control over supply chain • We encompass all critical capabilities .Process development. Submission of API dossier. ASIASTAR.
China) : 15-20 new products launched annually : Australia.Our Businesses : Branded Finished Dosages • Track Record • Market Presence • Significant Presence • Market Sales Force • Focus on New Product Launches • Geography Expansion • Building Scale : Consistent growth and sustainable delivery of profits in last 16 quarters : Products in over 45 countries : India (Ranked 10th) Russia (Ranked 14th in retail segment) : Over 2. Russia. Brazil.000 (India. Turkey : South Africa. Mexico . New Zealand.
Our Businesses : Branded Finished Dosages Broad Therapeutic Area Coverage .
1 in 8 countries No. 1 in 5 countries No.Our Businesses : Branded Finished Dosages More than 200 brands collectively Top Brands Omez (Omeprazole) Stamlo (Amlodipine) Nise (Nimesulide) Ciprolet (Ciprofloxacin) Ketorol (Ketorolac) Enam (Enamapril) No. 1 in 7 countries No. 1 in 14 countries No. 1 in 5 countries No. 1 in 2 countries .
Our Businesses : Branded Finished Dosages Global Oncology – Niche Therapeutic Area Leading position in India.Anti-Hormonal & also the Supportive Care Successful track record in business development & strategic alliances . India. growing at ~ 40% No 1 in the Filgrastim and Oxaliplatin markets No 2 in the Gemcitabine. Europe. Docetaxel and Temozolomide markets Global commercialization presence in US.Russia. South Africa & Brazil Strong Biologics & Cytotoxic Manufacturing Infrastructure to address the need of Oncology Market Robust portfolio of Targeted Therapies. Cytotoxic .
metabolic disorders and cancer : For enhancing pre-clinical pipeline : Both in-house and through partnerships • Focus : Core therapeutic areas with a project-based approach : Over 300 • Scientists . India for analog based approach Atlanta.Our Businesses : Discovery Research Two Discovery Research Centers Hyderabad. with focus on cardiovascular. USA for target-based approach • NCEs under development • Calibrated Investments • Accelerating Clinical Development : Three.
Biologics.Our Businesses : Specialty Pharmaceuticals Building A Bridge : A branded. Micro-Spheres) Current internal compounds under pre-clinical and clinical development (Ex. NCEs. innovation-based business of differentiated products :Between Core Businesses and Ongoing Discovery Efforts Technologies acquired from Trigenesis 7 Products with marketing rights across geographies and technologies Internally developed proprietary drug delivery platforms (Ex. Targeted Business Development Effort : To accelerate market entry & achieve critical mass . etc) • Focus TAs : Dermatology and Oncology • Strong.
Our Businesses : Biologics Aspirations • Build a world-class Biosimilar development and commercialization organization • Leverage capabilities to accelerate the move up the Biologics Value Chain Products Grafeel® (biosimilar G-CSF) launched in India and multiple other geographies including Latin America. South East Asia & CIS countries Reditux® (biosimilar rituximab) launched in India Medium term entry in Europe and North America Pipeline Two products in / near clinical development Six products in pre-clinical development .
Our Businesses : Biologics People Team of 250 with 35 PhDs comprising scientists with significant experience in big biotech/pharmaceutical companies in US/EU Development Infrastructure R&D facility that can accommodate parallel development of upto four products with state-of-art facilities World class animal facility dedicated to Biologics for preclinical studies Manufacturing Capacity Mammalian cell culture capacity: 800 (4 X 200) Litres Microbial fermentation capacity Large-scale mammalian cell culture capacity expansion (15000 Litres) by 2010 Integrated fill-finish capabilities .
India Atlanta. Approved by USFDA. TPP (Canada) One FDA-Inspected plant in USA : One in India. With ISO 14001 and ISO 9001 certifications.3 million litres reaction volume : Six in India. USA . UK more than 2.Infrastructure Bandwidth • API Facilities : Six FDA-Inspected plants in India One FDA-Inspected plant in Mexico One FDA-Inspected plant in Mirfield. TGA (Australia). MHRA (UK). ANVISA (Brazil). audited by multiple regulatory agencies Finished Dosage Units Biologics Facility Custom Pharmaceutical Services : Two Technology Development Centres (TDC) in India and One in Cambridge. UK Discovery Research Centres : Hyderabad. MCC (South Africa).
regulatory and IP expertise Regulatory Team | Over 55 IP Team | Over 50 . flexibility and reliability Effective combination of chemistry and formulation skills with legal. Creating a Prolific Global Generics Product Development Engine R&D Team | Over 700 Integrate the product development activity of APIs and Finished Dosages Increase speed.Integrated Product Development – a strong platform tate-of-the-art IPDO Facility First of its kind in India.
Integrated Business Model IP Framewo rk Drug Discovery R&D Expertise Pharmaceutical Services and Active Ingredients Finished Dosages Manufact uring & Operation al Excellenc e Sales & Marketin g Capabilit ies trategic value across the value-chain bility to secure long-term cost competitivene ss everage R&D (scale & infrastructure) across business .
Corporate Governance Committed to progressive governance Adopted international governance practices & processes Commitment to highest standards of disclosures & transparency Only Pharma company from India to be listed on the New York Stock Exchange SOX Compliance Code of Business Ethics .
Financial Snapshot (USD Mn) Financial Year .
BASF: Strengthen the supply chain for North America betapharm : Access to 2nd largest generics market globally with significant entry barriers Falcon (Mexico) : Build critical mass and broad-base customer relationships with innovator companies in the Custom Pharmaceutical Services segment Acquisitions • • (1) Chronic Obstructive Pulmonary Diseases .Business Development Authorized Generics & Patent Settlements • • Merck deal : Launched the AG version of Zocor® & Proscar® in June’06. Settled Propecia GSK deal : Settlement in October’06 and enables early launch of AG version of Immitrex® in the US in Q4 CY08 ahead of patent expiry in Feb 09 Pursuing Partnership & Alliances • • Co-development & commercialization of NCEs : Rheoscience for Balaglitazone. ClinTec International for DRF 1042 Expanding Portfolio : Partnerships and alliances in the US/EU. global in-licensing for rest of the world markets • • Dow Pharma: A non-exclusive license to Dow’s Pfenex Expression Technology™ for biocatalysis development. Argenta for new approach to treat COPD(1).
• World wide employees • India • Germany • Rest of Europe • North America • Mexico • Rest of the World : 9500+ : 7878 : 394 : 101 : 109 : 322 : 771 1700+ 3300+ 3300 + 40 + Research & Scientific staff Marketing & Sales force Manufacturing staff Nationalities .
People – Our DNA • Attract. Develop and Retain • Create • Develop and Nurture • Promote • Build : Multi-skilled high-performers : A learning organization : Young leaders : Teamwork and collaboration : A diverse workforce and meritocracy .
People – Our DNA • Talent Management • Learning and Development • PerfECT (Performance Enhancement and Coaching Tools) • Organizational Climate Survey • Annual Celebrations to recognize excellence • 3600 feedback Survey • Alumni Network – Friends Forever Fast-tracker program Acceleration of career growth for high-performers .
Reditux (rituximab) launched Fastest Indian Pharma Company to cross $1billion in annual revenue 1st manufacturing company to be Sarbanes-Oxley certified 1st authorized generic deal with multinational pharma Key acquisition betapharm (Germany) Key acquisition “Falcon” (Mexico) 1st to be listed on the New York Stock Exchange 1st to out-license an NCE to a multinational pharma Discovery Research commenced 2008 2007 2006 2005 2001 1997 1993 2006 2006 2005 2001 1997 1993 .Track record 2008 2008 2007 2007 2006 Acquisition of BASF’ facility at Shreveport. UK Sites World’s first biosimilar monoclonal anti-body . US Aquisiton of Dowpharma SmallMolecules business associated with Dow’s Mirfield and Cambridge.
.Commitment to Sustainability We are committed to Access and Affordability of medicines through a business model that prioritizes the manufacture of affordable generic medicines and investment in discovery of new molecules that meet unmet and poorly met medical needs.
Reddy’s Foundation – Livelihoods & Education Patient Assistance Programs & DRHFE Employee Engagement .Triple Bottom Line Approach… Dr. Product safety (Pharmco vigilance) Zero Liquid Discharge & SHE technologies Environment: ISO 14001 & OHSAS 18001certified facilities Suppliers: mySAP business Suite Corporate Governance Employees: Policies / Talent Mgmt Board / Leadership devpt / BPE To help people lead healthier lives through global access to medicine .Volunteer Program & Power of Ten Customer: FDA approved.
000 : To create 1 million livelihoods by 2010 : Sri Lanka and Vietnam : With major corporates for customized manpower training Result: Over 80% beneficiaries reported an increase in their earnings through successful recruitment or by becoming entrepreneurs .50.Triple Bottom Line Approach… • Nurture & Train • Livelihoods created so far • Aim • Centres • Tie-up : Employable young adults from financially weak backgrounds : 1.
Achievements NDTV Profit Business Leadership Awards 2007 Business Leader in the Pharmaceutical Sector Dun & Bradstreet American Express Corporate Awards 2007 Best Corporate Social Responsibility Initiative 2007 BSE .India Pharma Excellence Awards 2006-07 for sustained Growth The Indian Express Best Employers in India 2007 Award Hewitt Associates & The Economic Times Asia-Pacific HRM Congress 2007 Global HR Excellence Award for Innovative HR Practices .